Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach?
Novel pharmacological therapies are in development for cancer, ranging from conventional chemotherapeutic drugs to molecular targeted drugs, antibody-based drugs, and immune checkpoint inhibitors, which are developed using new technologies. However, the increasing cost of new drug development is increasing the costs of national healthcare and putting pressure on government finances worldwide. Under these circumstances, drug repositioning (i.e. discovering novel effects of existing drugs, thereby allowing their use to treat other diseases) has become a major focus because of reliability and cost reduction. It is becoming increasingly clear that statins (currently used for treating dyslipidemia) can be effective in the prevention of coronary disease, heart failure, and arrhythmia. Epidemiological as well as basic research studies and epidemiological surveys have showed that statins have a suppressive effect on cancers and that they have an antitumor effect on colorectal, prostate, breast, cervical, endometrial, and ovarian cancers. Given the pharmacological mechanism of action of statins, they may have an antitumor effect on cancer types in which the mevalonate pathway is activated as well as on tumors with p53 mutations. To investigate this further, it would be necessary to conduct a large-scale survey after confirming the clinical background of patients as well as their mutational status, and therefore, great hope has been placed on the role of academia and public institution...
ConclusionsThese consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time when further evidence is available to guide our approach.Patient summaryThis report summarises findings from an international, multistakeholder project organised by the EAU and ESMO. In this project, a steering committee identified areas of bladder cancer management where there is currently no good-quality evidence to guide treatment decisions. From this, they developed a series of proposed statements, 71 of which achieved consensus by a large group of experts in the field of...
Is there any difference in sensitivity to kidney function between men and women? Paterson et al. have focused on sex differences in chronic kidney disease. Surprisingly, their experimental results show that only one microRNA, miR-146b-5p, affected the susceptibility of renocardiac pathology. They generated miR-146b knockout rats and found that miR-146b−/− females developed exacerbated renal hypertrophy and fibrosis and had less cardiac remodeling. Although miR-146b-5p has been reported to be upregulated in various types of cancers, this article reveals the novel role of miR-146b in the kidney.
The objective of this study is to assess information, motivation, and behavioral skills associated with willingness to receive an HPV test instead of a Pap test among women. The sample included U.S. 812 women, ages 30 to 65 years. Participants completed an online survey in 2018. The Information, Motivation, and Behavioral Skills (IMB) model was used to measure predictors of willingness for HPV testing. The outcome variables were willingness to receive the HPV test instead of the Pap test, with and without time interval details. Logistic regression modeling was used with SAS 9.4. Over half of the sample (55%) were willing...
Publication date: Available online 20 November 2019Source: European Journal of Surgical OncologyAuthor(s): Isabel T. Rubio, Michalis Kontos, M.J. Vrancken-Peeters, Roman Rouzier, Anita Rohini, Viviana Galimberti, Niels Kroman, Carmela Caballero, Shinji Ohno, BIG Task Force Surgical Trials
Conclusions: Our findings suggest that some subsets of XPD patients may be at risk of radiosensitivity reactions and treatment with statins and bisphosphonates may be an interesting approach of radioprotection countermeasure. Different mechanistic models were discussed to better understand the potential specificity of the p.[Arg683Trp];[Arg616Pro] XPD mutations . PMID: 31738647 [PubMed - as supplied by publisher]
Conclusions: In this review, we examine the role of flavonoids as potential radiosensitizers, review the underlying molecular mechanisms and discuss their potential usefulness in improving cancer radiotherapy. It is emphasized that obtaining a deeper insight into the molecular mechanisms underlying the combined action of flavonoids and ionizing radiation may provide new directions for radiobiological research applicable to the much needed enhanced selective tumor cytotoxicity to treatment agents. PMID: 31738629 [PubMed - as supplied by publisher]
Authors: Hsu TI, Chen YJ, Hung CY, Wang YC, Lin SJ, Su WC, Lai MD, Kim SY, Wang Q, Qian K, Goto M, Zhao Y, Kashiwada Y, Lee KH, Chang WC, Hung JJ Abstract [This corrects the article DOI: 10.18632/oncotarget.3701.]. PMID: 31741716 [PubMed - in process]
Conclusions: Buparlisib was well tolerated, however efficacy was limited despite selection of PI3K pathway aberrations. Future studies may provide insight into buparlisib efficacy by refining the molecular selection of different tumor types. PMID: 31741715 [PubMed]
Conclusions: Although liquid biopsy remains challenging, a combination of SPAG6, NKX2-6, ITIH5 and PER1 (SNiPER) provides a promising tool for blood-based breast cancer detection. PMID: 31741713 [PubMed]
Authors: Li X, Teng S, Zhang Y, Zhang W, Zhang X, Xu K, Yao H, Yao J, Wang H, Liang X, Hu Z Abstract [This corrects the article DOI: 10.18632/oncotarget.16789.]. PMID: 31741718 [PubMed - in process]